Skip to content
Screener

Inhibrx Biosciences, Inc. INBX Business Segments — Research And Development Expense, Contract Manufacturing

Similar metrics at other companies

Avalo Therapeutics logo
AVTXReportable Segment — Research and development expense
$23.42M+66.4%
Guardant Health logo
GHReportable Segment — Research and development expense
$76.59M+2.3%
Viridian Therapeutics, Inc. logo
VRDNReportable Segment — Segment research and development expense
$64.19M-21.1%
Momentus logo
MNTSReportable Segment — Research and development expenses
$4.17M+118%
Powell Industries logo
POWLReportable Segment — Research and development expenses
$4.29M+56.2%
Eos Energy Enterprises, Inc. logo
EOSEReportable Segment — Research and development expenses
$10.51M+45.9%

Other financials

Income statement

See full
Revenue--100%
Operating income-$30.9M+27.9%
Net income-$33.4M+22.8%
EPS (diluted)-$2.15+23.2%

Balance sheet

See full
Cash & equivalents$161.7M-25.3%
Total debt$180.9M+69.8%
Total equity-$21.0M-122%
Total assets$184.0M-24.2%

Cash flow

See full
Operating cash flow-$38.0M-5.9%
CapEx--100%
Free cash flow-$38.0M-5.9%

Valuation

See full
Market cap$1.3B+320%
Enterprise value$1.32B+474%

Profitability

See full
Operating margin-10,386.5%-5,025pp
Net margin-10,773.5%-878,492pp
FCF margin-9,986.5%-4,727pp

Returns & leverage

See full
Return on equity-197.8%-2,158pp
Debt / equity13.4×+13.3×
Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept inhibrx:ResearchAndDevelopmentExpenseContractManufacturing.

The source filing: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 4:02 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0002007919-26-000027
Line itemTHREE MONTHS ENDEDMARCH 31, 2026THREE MONTHS ENDEDMARCH 31, 2025
Research and development expense
Clinical trials$(9,180)$(13,265)
Personnel(8,527)(9,326)
Contract manufacturing(2,043)(8,550)
Equipment, depreciation, and facility(2,561)(2,583)
Other research and development(2,906)(3,153)
Total research and development expense(25,217)(36,877)
General and administrative expense

Item 1. Financial Statements (unaudited)

FAQ

What is Inhibrx Biosciences, Inc.'s business segments — research and development expense, contract manufacturing?
Inhibrx Biosciences, Inc. (INBX) reported business segments — research and development expense, contract manufacturing of $2.04M in Q1 2026.
How has Inhibrx Biosciences, Inc.'s business segments — research and development expense, contract manufacturing changed year-over-year?
Inhibrx Biosciences, Inc.'s business segments — research and development expense, contract manufacturing decreased by 76.1% year-over-year, from $8.55M to $2.04M.
What does business segments — research and development expense, contract manufacturing mean?
This metric tracks costs associated with outsourcing the production of drug candidates to third-party manufacturing organizations. It represents the financial commitment to scaling up manufacturing processes for clinical supply. Changes in this metric often correlate with the transition from early-stage development to larger clinical trials.

Ask your AI about Inhibrx Biosciences, Inc.'s business segments — research and development expense, contract manufacturing.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude